July 23, 2016 6:10 AM ET

Biotechnology

Company Overview of N-of-One, Inc.

Company Overview

N-of-One, Inc., a molecular decision support company, provides clinicians with interpretation of molecular test results. It provides disease-specific biological relevance, clinical evidence, associated therapies, and references. The company also interprets next generation sequencing (NGS) of solid and hematological tumors, circulating tumor cells and DNA, copy number analysis, and immunohistochemistry. In addition, it offers PrecisionInsights, a clinical interpretation report for 15-20 gene NGS panels, delivering concise clinical and scientific evidence for each biomarker in the context of the cancer sub type and a list of therapeutic options; and TRIALMATCH, a patient-specific clinical tria...

430 Bedford Street

Suite 390

Lexington, MA 02420

United States

Founded in 2007

Phone:

617-202-9808

Fax:

781-652-8220

Key Executives for N-of-One, Inc.

Chairman and Chief Executive Officer
Age: 64
Founder, President, Chief Medical Officer and Director
Chief Financial Officer and Director
Age: 53
Vice President of Operations
Vice President, Secretary and General Counsel
Age: 51
Compensation as of Fiscal Year 2016.

N-of-One, Inc. Key Developments

N-Of-One to Supply Admera Health with Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One reported that Admera Health has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne. N-of-One's patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient's molecular tests to therapeutic strategies, including clinical trials. N-of-One noted that the OncoGxOne is a next-generation sequencing panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials.

Macrogen Selects N-of-One to Provide Patient-Specific Interpretation for the Launch of New Clinical Next-Generation Sequencing Panels

N-of-One, Inc. announced that Macrogen Corp. has selected N-of-One to provide high-quality clinical interpretation for its newly launched clinical next-generation sequencing (NGS) panels used for cancer patients. Financial terms of the agreement are not disclosed. N-of-One’s patient-specific analysis identifies therapeutic options based on each patient’s specific molecular profile identified by the sequencing data. These therapeutic options include therapies in guidelines, off label therapies, and the most relevant clinical trials prioritized based on molecular and geographical relevance.

Wuxi Nextcode Selects N-of-One, Inc. for Global Relationship, to Provide Clinical and Scientific Evidence for Interpretation for Cancer

N-of-One, Inc. announced that it has signed a global agreement with WuXi NextCODE to provide clinical and scientific evidence for delivering the best personalized treatment options based on the results of WuXi NextCODE tumor-normal genome sequence interpretation, which identifies key driver mutations in individual tumors. WuXi NextCODE manages and interprets more genomes than any other system in the world. It is deploying its unique database, informatics and reporting system for major precision medicine efforts in the UK, US, China, Qatar and elsewhere in cancer, rare disease, and drug discovery and development. N-of-One clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient's specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient. The global agreement between the companies enables them to collaborate on WuXi NextCODE’s work with the UK 100,000 Genomes Project and to tailor offerings for other geographies in the months ahead.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 23, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact N-of-One, Inc., please visit n-of-one.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.